---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092756"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:54:13.316270+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q2 net loss $18.7M; cash remains $373.8M; IND cleared for TYRA-430; ACH IND on track

## Summary
- Q2 net loss $18.7M ($13.3M in Q2 2023); R&D $18.0M; cash $373.8M, runway through at least 2026.
- FDA cleared IND for TYRA-430 (FGFR4/3 biased inhibitor) for Phase 1 in HCC and other solid tumors.
- TYRA-300: preclinical proof-of-concept in hypochondroplasia; ACH IND submission on track for 2H24.
- CMO Hiroomi Tada to depart by year-end; external search underway; S&T Committee guiding transition.
- SURF301 Phase1 initial results for TYRA-300 expected at a scientific congress in 2H24.

## SEC filing metadata
- accession: 0000950170-24-092756
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017024092756/0000950170-24-092756-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017024092756/tyra-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092756
- JSON: https://secwatch.observer/filing/0000950170-24-092756.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092756.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.